drugset / Trial / NCT01484184

Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury

NCT01484184

RandomizedFactorialDouble-blindTreatment

Summary

As a first-in-class (Central Pattern Generator or CPG activator) approach, this tritherapy candidate called SPINALON has been identified and is currently under development for its capacity to temporarily induce episodes of involuntary locomotor movements. The primary objective of this Phase I/IIa study is to assess safety and tolerability of a single escalating dose of SPINALON (levodopa + carbidopa + buspirone) in chronic spinal cord-injured patients. As a secondary objective, preliminary evidence of efficacy will also be sought.

Timeline

Start
2013-07
Primary completion
2015-08
Completion
2015-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Buspirone Small molecule
Comparator Levodopa Small molecule
Comparator cardidopa Unknown

Indications